Navidea Biopharmaceuticals Announces NIH Grant Award to UC San Diego for Clinical Study Evaluating Tc99m Tilmanocept as a Kidney Imaging Agent May 11, 2021
Navidea Biopharmaceuticals to Host First Quarter 2021 Earnings Conference Call and Corporate Update May 4, 2021
Navidea Biopharmaceuticals Announces Acceptance of Therapeutics Focused Abstract for Presentation at the Frontiers in Cancer Immunotherapy Symposium Apr 15, 2021
Navidea Biopharmaceuticals to Host Fourth Quarter 2020 Earnings Conference Call and Corporate Update Mar 17, 2021
Navidea Biopharmaceuticals to Present at the H.C. Wainwright Global Life Sciences Virtual Conference Mar 2, 2021
Navidea Biopharmaceuticals Announces Submission of Formal Type B Meeting Request with FDA and Launch of NAV3-32 Phase 2B Trial in Rheumatoid Arthritis Feb 8, 2021
